Table I. Proposed biomarkers of cardiac ischemia and coronary plaque instability and rupture.
Figure 1. Criteria to be satisfied for definitive clinical implementation of a cardiac biomarker.
Figure 2. Scheme of a cost-effectiveness trial for a new cardiac diagnostic biomarker.
Table II. Surrogate approaches employed in the evaluation of biomarkers for reversible myocardial ischemia.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.